Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. The loss of a shot at a milestone prompted OPM to lay off ...

French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and digital twins to help discover and develop new therapies for cancer.

GAS2 is a cytoskeletal regulator that interacts with both F-actin and microtubules. Here, cryo-EM structures of GAS2 domains ...

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. Fresh with a new brand identity, the ...